Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Diana F. Florescu; Megan A. Keck

doi:10.1586/14787210.2014.948847

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Diana F. Florescu, Megan A. Keck

Research output: Contribution to journal › Review article › peer-review

78 Scopus citations

Abstract

CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

Original language	English (US)
Pages (from-to)	1171-1178
Number of pages	8
Journal	Expert Review of Anti-Infective Therapy
Volume	12
Issue number	10
DOIs	https://doi.org/10.1586/14787210.2014.948847
State	Published - Oct 1 2014

Keywords

BK virus
Brincidofovir
CMX001
JC virus
adenovirus
cytomegalovirus
dsDNA virus
molluscum
orthopoxvirus
vaccinia virus

ASJC Scopus subject areas

Microbiology
Microbiology (medical)
Virology
Infectious Diseases

Access to Document

10.1586/14787210.2014.948847

Cite this

@article{4216f3ca12fa4d2f82f69812ff8b9e20,

title = "Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses",

abstract = "CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.",

keywords = "BK virus, Brincidofovir, CMX001, JC virus, adenovirus, cytomegalovirus, dsDNA virus, molluscum, orthopoxvirus, vaccinia virus",

author = "Florescu, {Diana F.} and Keck, {Megan A.}",

note = "Funding Information: Florescu DF has received a grant from Chimerix and has received consultancy fees from Chimerix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",

year = "2014",

month = oct,

day = "1",

doi = "10.1586/14787210.2014.948847",

language = "English (US)",

volume = "12",

pages = "1171--1178",

journal = "Expert Review of Anti-Infective Therapy",

issn = "1478-7210",

publisher = "Expert Reviews Ltd.",

number = "10",

}

TY - JOUR

T1 - Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

AU - Florescu, Diana F.

AU - Keck, Megan A.

N1 - Funding Information: Florescu DF has received a grant from Chimerix and has received consultancy fees from Chimerix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2014 Informa UK, Ltd.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

AB - CMX001 (hexadecyloxypropyl-cidofovir, Brincidofovir) is a broad spectrum, lipid conjugate of cidofovir that is converted intracellularly into the active antiviral, cidofovir diphosphate. The lipid conjugation results in oral bioavailability, higher intracellular concentrations of active drug, lower plasma concentrations of cidofovir and increased antiviral potency against dsDNA viruses.

KW - BK virus

KW - Brincidofovir

KW - CMX001

KW - JC virus

KW - adenovirus

KW - cytomegalovirus

KW - dsDNA virus

KW - molluscum

KW - orthopoxvirus

KW - vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=84907059423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907059423&partnerID=8YFLogxK

U2 - 10.1586/14787210.2014.948847

DO - 10.1586/14787210.2014.948847

M3 - Review article

C2 - 25120093

AN - SCOPUS:84907059423

SN - 1478-7210

VL - 12

SP - 1171

EP - 1178

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

IS - 10

ER -

Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this